title: The Rationale for Optimal Combination Therapy With Sipuleucel-T for Patients With Castration-resistant Prostate Cancer.
abstract: Immunotherapy encourages the recipient's own immune response to destroy cancer cells, and current evidence suggests that immunotherapies may be most beneficial in early metastatic castration-resistant prostate cancer (mCRPC). Sipuleucel-T is the first therapeutic cancer vaccine to be approved by both the US Food and Drug Administration and European Medicines Agency for the treatment of asymptomatic or minimally symptomatic mCRPC. Combining immunotherapy with other treatments may have potent anticancer effects; cytoreductive therapies can release tumor antigens and promote a proinflammatory environment that could augment immunotherapies. However, some cytoreductive agents or coadministered drugs may be immunosuppressive. Understanding these interactions between different mCRPC treatment modalities may offer further potential to improve patient outcomes.
authors.affiliation: Associated Medical Professionals of New York, Syracuse, NY.
authors.forename: Vladimir
authors.initials: V
authors.lastname: Mouraviev
authors.affiliation: Associated Medical Professionals of New York, Syracuse, NY.
authors.forename: Neil
authors.initials: N
authors.lastname: Mariados
authors.affiliation: Urology Associates, Nashville, TN.
authors.forename: David
authors.initials: D
authors.lastname: Albala
authors.affiliation: Urology Associates, Nashville, TN.
authors.forename: Raoul S
authors.initials: RS
authors.lastname: Concepcion
authors.affiliation: Carolina Urologic Research Center, 21st Century Oncology, Myrtle Beach, SC.
authors.forename: Neal D
authors.initials: ND
authors.lastname: Shore
authors.affiliation: Dendreon Corporation, Seattle, WA.
authors.forename: Robert B
authors.initials: RB
authors.lastname: Sims
authors.affiliation: University College of London, London, UK.
authors.forename: Mark
authors.initials: M
authors.lastname: Emberton
authors.affiliation: Associated Medical Professionals of New York, Syracuse, NY.
authors.forename: Christopher M
authors.initials: CM
authors.lastname: Pieczonka
keywords: Combination therapy; Prostate cancer; Sipuleucel-T